RCKTW (Rocket Pharmaceuticals, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by RCKTW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-28 | John Militello | See Remarks | MIXED | — | — |
| 2026-05-26 | Gaurav Shah | CEO | MIXED | — | — |
| 2026-05-21 | John Militello | See Remarks | Sell | — | — |
| 2026-05-21 | Martin Wilson | General Counsel | Sell | — | — |
| 2026-05-21 | Gaurav Shah | CEO | Sell | — | — |
| 2026-05-14 | John Militello | See Remarks | Sell | — | — |
| 2026-05-14 | Martin Wilson | General Counsel | Sell | — | — |
| 2026-05-14 | Gaurav Shah | CEO | Sell | — | — |
| 2026-05-11 | Sarbani Chaudhuri | See Remarks | Sell | — | — |
| 2026-02-20 | John Militello | See Remarks | Sell | — | — |
| 2026-02-20 | Gaurav Shah | CEO | Sell | — | — |
| 2026-02-20 | Martin Wilson | General Counsel | Sell | — | — |
| 2026-02-18 | John Militello | See Remarks | Sell | — | — |
| 2026-02-18 | Martin Wilson | General Counsel | Sell | — | — |
| 2026-02-18 | Gaurav Shah | CEO | Sell | — | — |
| 2026-02-13 | John Militello | See Remarks | A | — | — |
| 2026-02-13 | Martin Wilson | General Counsel | A | — | — |
| 2026-02-13 | Gaurav Shah | CEO | A | — | — |
| 2026-02-13 | Christopher James Stevens | Chief Operating Officer | A | — | — |
| 2026-02-13 | Syed Ali-aamir Rizvi | Chief Medical Officer | A | — | — |
| 2026-02-13 | Sarbani Chaudhuri | See Remarks | A | — | — |
| 2026-01-06 | Elisabeth Bjork | Director | Buy | — | — |
| 2025-11-20 | Martin Wilson | General Counsel | Sell | — | — |
| 2025-11-20 | John Militello | See Remarks | Sell | — | — |
| 2025-11-20 | Jonathan David Schwartz | See Remarks | Sell | — | — |
| 2025-11-20 | Gaurav Shah | CEO | Sell | — | — |
| 2025-11-10 | Martin Wilson | General Counsel | A | — | — |
| 2025-10-16 | John Militello | See Remarks | Sell | — | — |
| 2025-10-08 | Syed Ali-aamir Rizvi | Chief Medical Officer | A | — | — |
| 2025-10-03 | Peter Fong | Director | A | — | — |
| 2025-09-23 | RTW INVESTMENTS, LP | Director | MIXED | — | — |
| 2025-09-09 | Martin Wilson | General Counsel | A | — | — |
| 2025-09-09 | Jonathan David Schwartz | See Remarks | A | — | — |
| 2025-09-09 | John Militello | See Remarks | A | — | — |
| 2025-08-27 | Elisabeth Bjork | Director | Buy | — | — |
| 2025-08-20 | John Militello | See Remarks | Sell | — | — |
| 2025-08-20 | Martin Wilson | General Counsel | Sell | — | — |
| 2025-08-20 | Gaurav Shah | CEO | F | — | — |
| 2025-08-20 | Jonathan David Schwartz | See Remarks | Sell | — | — |
| 2025-08-18 | Martin Wilson | General Counsel | Sell | — | — |
| 2025-08-18 | John Militello | See Remarks | Sell | — | — |
| 2025-08-18 | Jonathan David Schwartz | See Remarks | Sell | — | — |
| 2025-08-06 | Christopher James Stevens | Chief Operating Officer | A | — | — |
| 2025-07-18 | Mikael Dolsten | Director | A | — | — |
| 2025-07-18 | CARSTEN BOESS | Director | A | — | — |
| 2025-07-18 | Elisabeth Bjork | Director | A | — | — |
| 2025-07-18 | Piratip Pratumsuwan | Director | A | — | — |
| 2025-07-18 | DAVID P SOUTHWELL | Director | A | — | — |
| 2025-07-18 | RODERICK WONG | Director | A | — | — |
| 2025-07-18 | Fady Ibraham Malik | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 18,236,124 | — |
| — | Director | 18,218,457 | — |
| — | CEO | 1,315,749 | — |
| — | General Counsel | 677,977 | — |
| — | Chief Operating Officer | 469,129 | — |
| — | See Remarks | 468,701 | — |
| — | Director | 415,346 | — |
| — | Chief Medical Officer | 407,874 | — |
| — | See Remarks | 299,064 | — |
| — | See Remarks | 267,510 | — |
| — | Director | 144,784 | — |
| — | Chief Financial Officer | 128,173 | — |
| — | See Remarks | 89,780 | — |
| — | See Remarks | 69,140 | — |
| — | Director | 53,333 | — |
| — | Director | 50,000 | — |
| — | Director | 44,220 | — |
| — | Director | 30,000 | — |
| — | Director | 30,000 | — |
| — | Director | 30,000 | — |
| — | Director | 30,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RCKTW quote page; the site-wide leaderboard is on the insider transactions hub.